Amsterdam, the Netherlands and Boston, Mass. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it will be implementing Clinical Pathways from the Dana-Farber Cancer Institute, a leading center of cancer research and treatment, and founding member of the NCI-designated Dana-Farber/Harvard Cancer Center, to establish best practices in cancer care. The Dana-Farber Clinical Pathways will be deployed through the Philips IntelliSpace Oncology Platform, providing clinical decision support to physicians via a patient-centric solution. The implementation will help oncologists quickly reach the most appropriate cancer treatments for patients, based on the unified view of the patient across diagnostic modalities and the embedded knowledge of Clinical Pathways, and can be delivered through existing EHR platforms.
Cancer is an incredibly complex set of diseases and the amount of information and treatment options available can be challenging to cope with for oncologists. Philips will leverage Dana-Farber Clinical Pathways to effectively map cancer patients to the appropriate treatment options. Philips will power this clinical decision support through its oncology informatics suite, which integrates radiology, pathology, genomics and EHR data to support pathways to scale precision medicine.
For example, in patients whose chronic myelogenous leukemia is progressing after first-line therapy, Dana-Farber Pathways helps physicians sort through over a dozen different possible resistance mutations and a handful of targeted therapies with very different side effect profiles to find the most appropriate treatment for that particular patient.
